Drugs / SSS59
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06944444 | Apr 2025 → Mar 2027 expected | cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06944444 ↗ |
| Modality | Monoclonal antibody | “A humanized antibody targeting MUC17” NCT06944444 ↗ |
| Route | Intravenous | “12 levels, QW IV” NCT06944444 ↗ |
| Target | MUC17 | “targeting MUC17” NCT06944444 ↗ |